Arbutus Biopharma Corp (ABUS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 642.12 is considered Overvalued compared with the five-year average of -8.90. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.86 to 3.36 according to relative valuation method. Compared to the current price of 4.67 USD , Arbutus Biopharma Corp By Overvalued By 39.01%.

Relative Value

Fair Zone

0.86-3.36

Current Price：4.67

39.01%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arbutus Biopharma Corp (ABUS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arbutus Biopharma Corp (ABUS) has a current Price-to-Book (P/B) ratio of 11.83. Compared to its 3-year average P/B ratio of 5.65, the current P/B ratio is approximately 109.46% higher. Relative to its 5-year average P/B ratio of 2.36, the current P/B ratio is about 401.82% higher. Arbutus Biopharma Corp (ABUS) has a Forward Free Cash Flow (FCF) yield of approximately -4.94%. Compared to its 3-year average FCF yield of -14.29%, the current FCF yield is approximately -65.40% lower. Relative to its 5-year average FCF yield of -13.90%, the current FCF yield is about -64.43% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ABUS competitors is 128.17, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS.O) exhibits a P/S ratio of 642.12, which is 400.97% above the industry average. Given its robust revenue growth of -60.49%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ABUS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ABUS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ABUS currently overvalued or undervalued?

What is Arbutus Biopharma Corp (ABUS) fair value?

ABUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arbutus Biopharma Corp (ABUS) is between 0.86 to 3.36 according to relative valuation method.

How does ABUS's valuation metrics compare to the industry average?

The average P/S ratio for ABUS's competitors is 128.17, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS) exhibits a P/S ratio of 642.12, which is 400.97% above the industry average. Given its robust revenue growth of -60.49%, this premium appears unsustainable.

What is the current P/B ratio for Arbutus Biopharma Corp (ABUS) as of Mar 03 2026?

As of Mar 03 2026, Arbutus Biopharma Corp (ABUS) has a P/B ratio of 11.83. This indicates that the market values ABUS at 11.83 times its book value.

What is the current FCF Yield for Arbutus Biopharma Corp (ABUS) as of Mar 03 2026?

As of Mar 03 2026, Arbutus Biopharma Corp (ABUS) has a FCF Yield of -4.94%. This means that for every dollar of Arbutus Biopharma Corp's market capitalization, the company generates -4.94 cents in free cash flow.

What is the current Forward P/E ratio for Arbutus Biopharma Corp (ABUS) as of Mar 03 2026?

As of Mar 03 2026, Arbutus Biopharma Corp (ABUS) has a Forward P/E ratio of -30.19. This means the market is willing to pay $-30.19 for every dollar of Arbutus Biopharma Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arbutus Biopharma Corp (ABUS) as of Mar 03 2026?

As of Mar 03 2026, Arbutus Biopharma Corp (ABUS) has a Forward P/S ratio of 642.12. This means the market is valuing ABUS at $642.12 for every dollar of expected revenue over the next 12 months.

ABUS Valuation